Smith & Nephew announces completion of Brainlab Orthopaedic Joint Reconstruction Business acquisition
Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, has completed the acquisition of the Brainlab orthopaedic joint reconstruction business. The acquisition supports Smith & Nephew’s strategy to invest in best-in-class technologies that further its multi-asset digital surgery and robotic ecosystem.
The Brainlab orthopaedic joint reconstruction business provides surgeons with digital workflow tools, from pre-operative planning to intraoperative navigation to post-operative evaluation and sharing. Used in more than 500 hospitals worldwide, the technology helps maximise precision and reproducibility and achieve desired outcomes for patients and surgeons. Smith & Nephew’s initial priority will be to integrate the Brainlab technology into NAVIO◊ 7.0, the next version of its surgical robotics system.
Smith & Nephew and Brainlab are also collaborating on developing additional applications to enhance Smith & Nephew’s digital surgery ecosystem.
The commercial terms of the acquisition have not been disclosed.
About Smith & Nephew
Smith & Nephew is a portfolio medical technology business that exists to restore people’s bodies, and their self-belief. Smith & Nephew has leadership positions in Orthopaedics, Advanced Wound Management and Sports Medicine, more than 16,000 employees and a presence in more than 100 countries. Annual sales in 2018 were $4.9 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN). For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com and follow us on Twitter, LinkedIn or Facebook.
Brainlab, headquartered in Munich, develops, manufactures and markets software-driven medical technology, enabling access to advanced, less invasive patient treatments.
Core products center on information-guided surgery, radiosurgery, precision radiation therapy, digital operating room integration, and information and knowledge exchange. Brainlab technology powers treatments in radiosurgery and radiotherapy as well as numerous surgical fields including neurosurgery, orthopaedic, ENT, CMF, spine and trauma.
Privately held since its formation in Munich, Germany in 1989, Brainlab has more than 12,850 systems installed in over 100 countries. Brainlab employs almost 1,400 people in 18 offices worldwide, including more than 420 Research & Development engineers, who form a crucial part of the product development team.